Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The actions of tuberoinfundibular peptide on the hypothalamo-pituitary axes
Autore:
Ward, HL; Small, CJ; Murphy, KG; Kennedy, AR; Ghatei, MA; Bloom, SR;
Indirizzi:
Hammersmith Hosp, Imperial Coll Sch Med, Endocrine Unit, London W12 0NN, England Hammersmith Hosp London England W12 0NN ne Unit, London W12 0NN, England
Titolo Testata:
ENDOCRINOLOGY
fascicolo: 8, volume: 142, anno: 2001,
pagine: 3451 - 3456
SICI:
0013-7227(200108)142:8<3451:TAOTPO>2.0.ZU;2-N
Fonte:
ISI
Lingua:
ENG
Soggetto:
MESSENGER-RIBONUCLEIC-ACID; GLUCAGON-LIKE PEPTIDE-1; PARATHYROID-HORMONE; PTH2 RECEPTOR; 39 RESIDUES; ANTERIOR-PITUITARY; SUPRAOPTIC NUCLEUS; IN-VITRO; RAT; EXPRESSION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
32
Recensione:
Indirizzi per estratti:
Indirizzo: Bloom, SR Hammersmith Hosp, Imperial Coll Sch Med, Endocrine Unit, Du CaneRd, London W12 0NN, England Hammersmith Hosp Du Cane Rd London England W12 0NN 0NN, England
Citazione:
H.L. Ward et al., "The actions of tuberoinfundibular peptide on the hypothalamo-pituitary axes", ENDOCRINOL, 142(8), 2001, pp. 3451-3456

Abstract

Tuberoinfundibular peptide is a recently discovered agonist for the PTH receptor-2; the latter has a wide distribution including the external zone ofthe median eminence of the hypothalamus, suggesting a role in neuroendocrine function. We have investigated the effects of tuberoinfundibular peptideon the hypothalamo-pituitary axes in vitro and in vivo. Tuberoinfundibularpeptide had effects on the hypothalamopituitary-adrenal axis with increased release of ACTH-releasing factor (tuberoinfundibular peptide 100 nm 4.4 +/- 0.6 pmol/ explant vs. control 2.9 +/- 0.4 pmol/explant, P < 0.001) and increased release of arginine vasopressin (tuberoinfundibular peptide 100 nm563.5 +/- 55.5 fmol/explant vs. control 73.4 +/- 9.6 fmol/explant, P < 0.01) from in vitro hypothalamic explants. Intracerebroventricular administration of tuberoinfundibular peptide and PTH(1-34) resulted in elevated plasmaACTH at 10 min post injection (saline 13.5 +/- 2.1 pg/ml, tuberoinfundibular peptide 3 nmol 32.3 +/- 4.0 pg/ml; P < 0.01 to saline: PTH(1-34) 10 nmol28.9 +/- 3.2 pg/ml: P < 0.05 to saline). Tuberoinfundibular peptide also had both in vitro and in vivo effects on the hypothalamo-pituitary-gonadal axis with increased release of LH-releasing hormone (tuberoinfundibular peptide 100 nm 28.5 +/- 5.1 fmol/explant vs. control 19.3 +/- 2.5 fmol/explant, P < 0.05) from in vitro hypothalamic explants. Both intracerebroventricular and peripheral administration of tuberoinfundibular peptide had effects on the hypothalamo-pituitary-gonadal axis. Intracerebroventricular injection of tuberoinfundibular peptide increased plasma LH (tuberoinfundibular peptide 10 nmol 0.70 +/- 0.09 ng/ml vs. saline 0.42 +/- 0.04 ng/ml at 10 min, P < 0.05). Intraperitoneal administration of tuberoinfundibular peptide also increased plasma LH (tuberoinfundibular peptide 30 nmol 0.53 +/- 0.09 ng/ml vs. saline 0.21 +/- 0.04 ng/ml at 10 min, P < 0.05). In addition to these actions on the hypothalamo-pituitary-adrenal and hypothalamo-pituitary-gonadal axes, an increased release of GH-releasing factor (GRF) from hypothalamic explants (tuberoinfundibular peptide 100 nm 770.9 +/- 90.7 pg/explant vs. control 657.8 +/- 77.7 pg/explant, P < 0.01) was observed. Overall, these data show the actions of tuberoinfundibular peptide on the hypothalamo-pituitary axes and suggest that it may play a role in the control of the hypothalamo-pituitary-adrenal and hypothalamo-pituitary-gonadal axes.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/09/20 alle ore 12:02:08